Movember London Centre of Excellence
A prostate cancer journey as unique as each man
No two men are the same, and neither are their prostate cancers. Funded in partnership with Movember, The London Centre of Excellence brought together world-leading researchers to explore those differences, paving the way for more precise ways to understand a man’s risk, diagnose his cancer, and find the treatment most likely to work for him.

When I came from Texas 23 years ago, the UK was called a desert of prostate cancer research…there is no doubt that London became one of the global leaders in prostate cancer translational clinical research.
Professor Ros Eeles - The Institute of Cancer Research
Using genetics to find men most at risk
Some men are born with genetic changes, called gene variants, that affect their risk of prostate cancer. Professor Ros Eeles and her team at the Institute of Cancer Research have identified gene variants that are linked to more aggressive disease, improving our understanding of how prostate cancer develops and helping pinpoint which men are at greater risk.
These gene variants have a big effect on an individual man’s risk, but they are rare in the population. For many more men, their risk is influenced by lots of common genetic changes.
On their own, each change only has a tiny effect, but when hundreds of these small changes are considered together, they add up to make a big difference. Professor Eeles has now identified over 400 changes that can be tested in each man to give a measure of overall risk, called a polygenic risk score.
From genetic risk to targeted screening
Thanks to the Centre of Excellence funding, Professor Eeles launched the PROFILE clinical trial, to find out if the genetic tests she has developed could be used to spot men who are likely to develop prostate cancer. PROFILE focusses on healthy men aged 40 to 69 who are at an increased risk, including men with a family history of prostate cancer, men of Black African and Black African-Caribbean ancestry, and men with a known genetic variant associated with the disease. Men participating in the trial provide a blood sample for genetic testing and are monitored over time for any signs of prostate cancer.
Men can still join the PROFILE trial to help researchers understand if genetic testing can help identify men at higher risk who would benefit from closer monitoring. Finding prostate cancer early makes it much easier to treat, as the cancer is less likely to have spread to other parts of the body.
The aim is to target screening more precisely, with different approaches for different people depending on their individual risk.
Finding out which cancers could become aggressive
Our investment in this personalised approach continues through our Transformational Impact Awards. Professor Eeles is joining forces with researchers from the Universities of East Anglia, Manchester, Oxford and Cambridge to combine genetics with artificial intelligence to work out which cancers are most likely to spread or return after treatment.
The aim is to develop a test that could predict whether a man’s cancer is likely to become aggressive, helping men at highest risk receive tailored treatment sooner, while sparing other men the side effects of treatments they may not need.
Screening at a much bigger scale
Professor Eeles is also one of the lead researchers on TRANSFORM, our groundbreaking £60m screening trial. One of the four screening approaches being tested combines a polygenic risk score, measured using a simple saliva test, in combination with a fast MRI scan.
The trial aims to find the best way to screen all men for prostate cancer and provide the crucial evidence needed to pave the way for a safe and accurate national screening programme.
Professor Charlotte Bevan - Imperial College London
Tiny pieces of genetic material with big potential
Professor Charlotte Bevan and her team at Imperial College London have taken a different, but complementary route towards making prostate cancer care more personal.
Their research focuses on microRNAs, tiny pieces of genetic material that help control how genes work. MicroRNAs also circulate around the body in the blood, raising the possibility that a blood test could provide valuable information about a man’s risk of cancer and response to treatment.
Predicting if treatments will work
The Centre of Excellence enabled Professor Bevan to access blood samples generously donated by men with advanced prostate cancer. The men were taking part in clinical trials of chemotherapy treatment led by Professor de Bono at the Institute of Cancer Research. By measuring the levels of several different microRNAs in men’s blood, Professor Bevan was able to identify men who were more or less likely to benefit from the chemotherapy.
In the future, blood tests like this could help doctors choose the treatment most likely to work for each man, rather than waiting to see if his cancer responds, as well as helping him avoid the side effects of treatments unlikely to benefit him.
Could microRNAs also help find prostate cancer?
Collaboration within the Centre of Excellence also enabled microRNAs to be studied in healthy men with an increased risk of prostate cancer, who were part of the PROFILE clinical trial led by Professor Eeles. Professor Bevan found that measuring the levels of a small group of microRNAs could help identify which men at higher risk develop prostate cancer.
Polygenic risk scores tell researchers about a man’s inherited risk, while microRNAs circulating in his blood could provide information about what is happening in his body at that particular time. The two teams will continue working together to investigate how these different sources of genetic information might be used in combination to develop the best possible way of identifying which men need closer monitoring to ensure their prostate cancer is caught early.
microRNAs as potential new therapies
Supporting the next generation of prostate cancer researchers is also a key achievement of the London Centre of Excellence. By helping future leaders develop and explore new avenues of research, the Centre’s investment can continue to benefit men for years to come.
Centre of excellence funding enabled Dr Claire Fletcher to develop her research career in Professor Bevan’s lab and her research has opened up an intriguing possibility: could microRNAs themselves become treatments?
Dr Fletcher identified a microRNA that can damage the DNA of prostate cancer cells without affecting healthy prostate cells. This damage makes the cancer cells more sensitive to several treatments, including PARP inhibitor drugs developed by Professor de Bono. Dr Fletcher has now gained further funding to develop her microRNA research into promising new therapies for men with advanced prostate cancer.
The London Movember Centre of Excellence has been truly transformative for my career progression. The data that I generated with others as part of this funding, in particular concerning microRNAs with key roles in prostate cancer, continues to inform my research today and has allowed me to obtain my current position of Associate Professor.
Following microRNA signals through the body
We continue to fund Professor Bevan’s cutting-edge research through a Transformational Impact Award investigating how prostate cancer cells communicate.
A range of signals, including circulating microRNAs, pass between cancer in the prostate and cancer that has spread to other parts of the body. By understanding these signals, Professor Bevan hopes to find new ways to treat advanced prostate cancer and help doctors tailor treatments to each man.
Professor Mark Emberton - University College London
Changing how prostate cancer is diagnosed
Professor Mark Emberton and his team at University College London pioneered research showing that scanning a man’s prostate before taking a biopsy made prostate cancer diagnosis much more accurate. A Magnetic Resonance Imaging (MRI) scan helped doctors spot any areas of the prostate that might contain cancer, and, if a biopsy was needed, doctors could use the scan to guide where in the prostate to take small samples from for testing. The team’s early findings led to the government funding a clinical trial called PROMIS, which found that MRI detected 93% of prostate cancers that needed treatment, compared with just 48% detected by the standard biopsy method used at the time.
The research also revealed that over a quarter of men could avoid having a biopsy altogether, if their MRI scan suggested they were unlikely to have prostate cancer that needed treatment. Thanks to the team’s groundbreaking work, MRI before biopsy is now part of the recommended NHS diagnostic pathway.
The Centre of Excellence created an environment in which these truly pivotal, practice-changing studies were conducted and published.
PROMIS for the future
Over 500 men who took part in the PROMIS trial generously allowed their MRI scans and biopsy images to be stored as a permanent collection to help prostate cancer researchers worldwide. The PROMIS dataset is already being used by researchers developing artificial intelligence (AI) tools that could help doctors interpret MRI scans quickly and even more accurately. Because the collection contains detailed information from men who didn’t have cancer, as well as men who had cancer that did or did not need treatment, the dataset is particularly valuable for developing tools that could help doctors make more personalised decisions for each man.
Knowing when treatment is needed
Finding prostate cancer earlier and more accurately is only part of the challenge. Doctors also need better ways of knowing which cancers need treating. Building on Professor Emberton’s work in the Centre of Excellence, we’re now funding a study called ReIMAGINE Life through our Transformational Impact Awards. Researchers will follow more than 1,000 men who've already had MRI scans and donated blood, urine and prostate biopsy samples. The team will link this data with men’s NHS records to track how their cancers develop over time.
The aim is to build a tool that can predict, at diagnosis, if a man’s cancer is likely to grow and spread, or if it may never cause any problems. This could mean men with high-risk cancers receive the treatment they need sooner, while men with low-risk cancers avoid unnecessary biopsies and treatments.
From better diagnosis to earlier detection
Professor Emberton is also bringing his MRI expertise to TRANSFORM, continuing the close collaboration with Professor Eeles, and other TRANSFORM lead researchers, that was central to the Centre of Excellence.
Together they hope to find the best way to detect harmful prostate cancers early, before symptoms develop. Advances in diagnosis have opened up new possibilities that weren’t available in previous studies on early detection.
Today we have a different set of tools including the ability to ‘see’ the cancer by virtue of MRI scans.
Testing fast MRI scans in TRANSFORM, alongside other approaches like polygenic risk scores, could provide the evidence needed for a national screening programme that saves men’s lives while avoiding biopsies and treatment for men who don’t need them.
Professor Johann de Bono - Institute of Cancer Research
Seeing prostate cancer differently
Men with advanced prostate cancer that has spread to other areas of the body have often been viewed as having the same disease and have been given the same treatments. But a treatment that works for one man may not work for another, meaning some men may experience difficult side effects without getting any benefits. Professor Johann de Bono and his team at the Institute of Cancer Research have shown that just as men are different from each other, so are their cancers.
The team looked carefully at the genetic variants men are born with, and any genetic changes that have taken place within the cancer itself. They found that there are many forms of advanced prostate cancer with important differences that affect how they respond to treatment.
Professor de Bono’s research provided key evidence that led to genetic testing becoming standard care for men with advanced prostate cancer. This has laid the foundations for a more personalised approach, as doctors can increasingly use information about a man’s cancer to identify treatments that are more likely to work for him.
Turning differences into precision treatment
One of the most important differences Professor de Bono identified was that some men with advanced prostate cancer have changes in genes involved in repairing damaged DNA. These genetic changes mean that their cancer is more likely to respond to a type of drug called a PARP inhibitor.
This research led to clinical trials of a PARP inhibitor called olaparib, which showed that men with advanced prostate cancer who have changes in their DNA repair genes respond well to the drug. As a result, olaparib became the world’s first precision medicine for prostate cancer and genetic testing can be used to identify which men are most likely to benefit.
We have changed prostate cancer care globally...without Prostate Cancer UK funding, this would not have happened.
Professor de Bono continues to identify additional genetic changes that make cancers respond well to olaparib, which may mean that even more men could benefit from the drug. The team also found that some men’s cancers stop responding to olaparib by reversing the genetic changes that made the treatment work. In the future, combining olaparib with a new drug that stops the cancer from reversing these changes could help men benefit from olaparib for longer.
Unlocking the potential of immunotherapy
Immunotherapy drugs work by helping a man’s own immune system recognise and kill cancer cells. Immunotherapy hasn’t generally worked well for prostate cancer, but Professor de Bono and his team have found that some men are more likely to respond. They identified a small group of men whose cancers are unable to correct mistakes in their DNA. As these mistakes build up, it can become easier for the immune system to recognise the cancer cells and kill them.
Although so far only a small proportion of men have been shown to benefit, some have had extraordinary, long-lasting responses, remaining well for more than ten years after treatment. This is opening up a potentially life-changing treatment approach for men who might otherwise have had very limited options.
In the future, immunotherapy may be able to benefit even more men. Following treatments such as hormone therapy, chemotherapy and radiotherapy, some cancer cells can remain in the body. The team have discovered that these remaining cancer cells can recruit cells from the immune system and change what they do. Instead of killing cancer cells, the immune cells help the cancer start to grow again.
We’re now funding Professor de Bono through a Transformational Impact Award, to test a new drug designed to stop cancer cells from recruiting immune system cells, which could help treatments for advanced prostate cancer work for longer.
The ASpiRE clinical trial is now open, and men with advanced prostate cancer that is no longer responding to hormone therapy could still take part.
A personal picture throughout treatment
Professor de Bono and his team have also developed blood tests that can reveal important information about a man’s cancer without the need for repeated biopsies. Prostate cancer can release tiny fragments of DNA into the blood, as well as whole cancer cells known as circulating tumour cells (CTCs). Blood tests taken before and during treatment can provide an up-to-date picture of the cancer and how it is responding.
This could help doctors tailor treatment decisions for each man, continue a treatment that is benefiting him, or considering alternative treatments sooner.
Pioneering personalised prostate cancer care
The London Centre of Excellence brought an exceptional mix of researchers and expertise together in a unique collaboration. Together, they have spearheaded a more personalised approach that has already changed prostate cancer care.
We’ve trained a generation of prostate cancer clinical scientists and researchers across the globe.
And there is more to come - the Centre has laid the foundations for progress to continue, with a growing pipeline of new treatment targets and ideas, many of which are already moving into drug development and clinical trials.
Just as importantly, the Centre has helped develop a thriving community of researchers ready to drive further advances in precision prostate cancer care.
The destination is clear: moving away from a one-size-fits-all approach towards a future where every man gets the tests, monitoring and treatment that are right for him, so more men can get the right care at the right time and live well for longer.